Key result
Metformin improves GTN-mediated dilatation by ~3% and lowers insulin dose in pediatric type 1 diabetes.
Why the study?
Does metformin improve vascular function in children with type 1 diabetes and BMI >50th percentile?
RCT (n=90)
Double-blind
randomized
No
Does metformin improve vascular function in children with type 1 diabetes and BMI >50th percentile?
Metformin improves vascular smooth muscle function and glycemic control while reducing insulin requirements in children with type 1 diabetes.
Supports adjunctive metformin for vascular benefits in overweight children with type 1 diabetes; extends evidence beyond glycemic effects.
Context Children with type 1 diabetes have vascular dysfunction preceding atherosclerosis. Early interventions are needed to reduce cardiovascular disease. Objective To evaluate the effect of metformin on vascular function in children with type 1 diabetes. Design Twelve-month double-blind, randomized, placebo-controlled trial. Setting Tertiary pediatric diabetes clinic. Participants Ninety children (8 to 18 years of age), >50th percentile body mass index (BMI), with type 1 diabetes. Intervention Metformin (up to 1 g twice a day) or placebo. Main Outcome Measure Vascular function measured by brachial artery ultrasound [flow-mediated dilatation/glyceryl trinitrate–mediated dilatation (GTN)]. Results Ninety participants were enrolled [41 boys, 13.6 (2.5) years of age, 45 per group], 10 discontinued intervention, and 1 was lost to follow-up. On metformin, GTN improved, independent of glycosylated hemoglobin (HbA1c), by 3.3 percentage units [95% confidence interval (CI) 0.3, 6.3, P = 0.03] and insulin dose reduced by 0.2 U/kg/d (95% CI 0.1, 0.3, P = 0.001) during 12 months, with effects from 3 months. Metformin had a beneficial effect on HbA1c at 3 months (P = 0.001) and difference in adjusted HbA1c between groups during 12 months was 1.0%; 95% CI 0.4, 1.5 (10.9 mmol/mol; 95% CI 4.4, 16.4), P = 0.001. There were no effects on carotid/aortic intima media thickness, BMI, lipids, blood pressure, or other cardiovascular risk factors. Median (95% CI) adherence, evaluated by electronic monitoring, was 75.5% (65.7, 81.5), without group differences. More gastrointestinal side effects were reported on metformin (incidence rate ratio 1.65, 95% CI 1.08, 2.52, P = 0.02), with no difference in hypoglycemia or diabetic ketoacidosis. Conclusions Metformin improved vascular smooth muscle function and HbA1c, and lowered insulin dose in type 1 diabetes children. These benefits and good safety profile warrant further consideration of its use.
No takes yet. Share an insight, caveat, or question.
Anderson et al. (2017) conducted an RCT in Type 1 diabetes (n=90). Metformin vs. Placebo was evaluated on Vascular function measured by brachial artery ultrasound (flow-mediated dilatation/glyceryl trinitrate-mediated dilatation [GTN]) (Difference 3.3 percentage units, 95% CI 0.3-6.3, p=0.03). Metformin improved glyceryl trinitrate-mediated dilatation by 3.3 percentage units (95% CI 0.3-6.3; P=0.03) and reduced insulin dose in children with type 1 diabetes over 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: